NT-ProBNP: a novel predictor of cardiovascular risk in type 2 diabetes

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a biomarker that has significant medical value in the assessment and management of cardiovascular diseases. The measurement of NT-proBNP levels in the blood provides valuable information for the risk, diagnosis, prognosis, and monitoring of various cardiovascular conditions. NT-proBNP levels have been found to provide valuable prognostic information in patients with acute coronary syndrome (ACS) and a risk predictor marker for CVD in type 2 diabetes patients. Elevated levels of NT-proBNP in CVD patients are associated with an increased risk of adverse cardiovascular events, including mortality. The measurement of NT-proBNP can help risk-stratify patients with heart failure and guide for superlative treatment decisions. The study aims to determine theNT-Pro BNP levels in type 2 diabetes patients with and without CVD in comparison to healthy controls in order to assess the risk of marker in CVD. The study also assess the differences between the three groups by evaluating the risk stratification of CVD in each group using a standard CVD risk tool. The outcome measures include the levels of NT-proBNP to find the risk of CVD. Also, the NT-ProBNP levels will be correlated with other markers such as fasting glucose, HbA1c, HDL, triglycerides, total cholesterol, LDL, micro-albuminuria, and creatinine to find their association. Risk stratification assessment for CVD using risk tools is also included in order to compare the risk analysis between the groups. Elevated levels of NT-proBNP in type 2 diabetes are associated with an increased risk of cardiovascular disease. The measurement of NT-proBNP can help risk-stratify patients with heart failure and guide for superlative treatment decisions.